Source:http://linkedlifedata.com/resource/pubmed/id/17728357
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
Pt 10
|
| pubmed:dateCreated |
2007-9-27
|
| pubmed:abstractText |
The neurodegenerative aspects of chronic progressive multiple sclerosis (MS) have received increasing attention in recent years, since anti-inflammatory and immunosuppressive treatment strategies have largely failed. However, successful neuroprotection and/or neuroregeneration in MS have not been demonstrated yet. Encouraged by the multifaceted neuroprotective effects of recombinant human erythropoietin (rhEPO) in experimental models, we performed an investigator-driven, exploratory open label study (phase I/IIa) in patients with chronic progressive MS. Main study objectives were (i) evaluating safety of long-term high-dose intravenous rhEPO treatment in MS, and (ii) collecting first evidence of potential efficacy on clinical outcome parameters. Eight MS patients, five randomly assigned to high-dose (48,000 IU), three to low-dose (8000 IU) rhEPO treatment, and, as disease controls, two drug-naïve Parkinson patients (receiving 48,000 IU) were followed over up to 48 weeks: A 6-week lead-in phase, a 12-week treatment phase with weekly EPO, another 12-week treatment phase with bi-weekly EPO, and a 24-week post-treatment phase. Clinical and electrophysiological improvement of motor function, reflected by a reduction in expanded disability status scale (EDSS), and of cognitive performance was found upon high-dose EPO treatment in MS patients, persisting for three to six months after cessation of EPO application. In contrast, low-dose EPO MS patients and drug-naïve Parkinson patients did not improve in any of the parameters tested. There were no adverse events, no safety concerns and a surprisingly low need of blood-lettings. This first pilot study demonstrates the necessity and feasibility of controlled trials using high-dose rhEPO in chronic progressive MS.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Oct
|
| pubmed:issn |
1460-2156
|
| pubmed:author |
pubmed-author:BartelsClaudiaC,
pubmed-author:EhrenreichHanneloreH,
pubmed-author:FischerBenjaminB,
pubmed-author:GoldRalfR,
pubmed-author:NaveKlaus-ArminKA,
pubmed-author:NorraChristineC,
pubmed-author:PaulusWalterW,
pubmed-author:SchellenbergerFelixF,
pubmed-author:SirénAnna-LeenaAL,
pubmed-author:StenderNikeN,
pubmed-author:StiefelMichaelM
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
130
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
2577-88
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:17728357-Adult,
pubmed-meshheading:17728357-Aged,
pubmed-meshheading:17728357-Cognition Disorders,
pubmed-meshheading:17728357-Disability Evaluation,
pubmed-meshheading:17728357-Dose-Response Relationship, Drug,
pubmed-meshheading:17728357-Erythropoietin,
pubmed-meshheading:17728357-Evoked Potentials, Motor,
pubmed-meshheading:17728357-Female,
pubmed-meshheading:17728357-Follow-Up Studies,
pubmed-meshheading:17728357-Humans,
pubmed-meshheading:17728357-Male,
pubmed-meshheading:17728357-Middle Aged,
pubmed-meshheading:17728357-Multiple Sclerosis, Chronic Progressive,
pubmed-meshheading:17728357-Neuroprotective Agents,
pubmed-meshheading:17728357-Neuropsychological Tests,
pubmed-meshheading:17728357-Psychomotor Performance,
pubmed-meshheading:17728357-Recombinant Proteins,
pubmed-meshheading:17728357-Treatment Outcome,
pubmed-meshheading:17728357-Walking
|
| pubmed:year |
2007
|
| pubmed:articleTitle |
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.
|
| pubmed:affiliation |
Division of Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Georg-August-University, Göttingen, Germany. ehrenreich@mpg.de
|
| pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|